Reproductive tract gene transfer

Fertility and Sterility

Volumn 80, Issue 3, 2003, Pages 475-484

  Daftary, Gaurang S ^a   Taylor, Hugh S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; HOXA10; Implantation; Infertility; Lipofection; Reproductive tract; Transduction; Transfection

Indexed keywords

FLUOROURACIL; GANCICLOVIR; RECOMBINANT DNA; RETROVIRUS VECTOR; VIRUS VECTOR;

CARDIOVASCULAR DISEASE; CELL DEATH; CONTRACEPTION; CORONARY ARTERY DISEASE; DATA BASE; DNA VECTOR; DRUG EFFICACY; FEMALE GENITAL SYSTEM; GENE EXPRESSION; GENE REPRESSION; GENE TRANSFER; GENETIC DISORDER; GENETIC PROCEDURES; GENETIC TRANSCRIPTION; HOMEOBOX; IMMUNE SYSTEM; MEDICAL RESEARCH; MEDLINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOPREGNANCY; REVIEW; SUICIDE GENE;

EID: 0042836927     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(03)00970-1     Document Type: Review

References (109)

1. Blaese R.M., Culver K.W., Miller A.D., Carter C.S., Fleisher T., Clerici M., et al. T lymphocyte-directed gene therapy for ADA-SCID initial trial results after 4 years . Science. 270:1995;475-480.
2. Alton E.W., Stern M., Farley R., Jaffe A., Chadwick S.L., Phillips J., et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis a double-blind placebo-controlled trial . Lancet. 353:1999;947-954.
3. Boucher R.C. Status of gene therapy for cystic fibrosis lung disease. J Clin Invest. 103:1999;441-445.
4. Knowles M.R., Hohneker K.W., Zhou Z., Olsen J.C., Noah T.L., Hu P.C., et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med. 333:1995;823-831.
5. Roth J.A., Nguyen D., Lawrence D.D., Kemp B.L., Carrasco C.H., Ferson D.Z., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 2:1996;985-991.
6. Liu Y., Thor A., Shtivelman E., Cao Y., Tu G., Heath T.D., et al. Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J Biol Chem. 274:1999;13338-13344.
7. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma . Cell. 79:1994;315-328.
8. Heise C., Hermiston T., Johnson L., Brooks G., Sampson-Johannes A., Williams A., et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 6:2000;1134-1139.
9. Drozdzik M., Qian C., Lasarte J.J., Bilbao R., Prieto J. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL). Gene Ther. 5:1998;1622-1630.
10. Palu G., Cavaggioni A., Calvi P., Franchin E., Pizzato M., Boschetto R., et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes a pilot study in humans . Gene Ther. 6:1999;330-337.
11. Kang W.K., Park C., Yoon H.L., Kim W.S., Yoon S.S., Lee M.H., et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts outcome of a phase I study . Hum Gene Ther. 12:2001;671-684.
12. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 95:1998;13141-13146.
13. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:1994;961-965.
14. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
15. Wong-Staal F., Poeschla E.M., Looney D.J. A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther. 9:1998;2407-2425.
16. Giordano F.J., Ping P., McKirnan M.D., Nozaki S., DeMaria A.N., Dillmann W.H., et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med. 2:1996;534-539.
17. Laitinen M., Hartikainen J., Hiltunen M.O., Eranen J., Kiviniemi M., Narvanen O., et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther. 11:2000;263-270.
18. Isner J.M., Pieczek A., Schainfeld R., Blair R., Haley L., Asahara T., et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 348:1996;370-374.
19. Daftary G.S., Taylor H.S. Efficient liposome-mediated gene transfection and expression in the intact human uterus. Hum Gene Ther. 12:2001;2121-2127.
20. Perkins A.S., Kirschmeier P.T., Gattoni-Celli S., Weinstein I.B. Design of a retrovirus-derived vector for expression and transduction of exogenous genes in mammalian cells. Mol Cell Biol. 3:1983;1123-1132.
21. Miller A.D. Retroviral vectors. Curr Top Microbiol Immunol. 158:1992;1-24.
22. Anderson W.F. Human gene therapy. Nature. 392:1998;25-30.
23. Rosenberg S.A., Aebersold P., Cornetta K., Kasid A., Morgan R.A., Moen R., et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 323:1990;570-578.
24. Boris-Lawrie K., Temin H.M. The retroviral vector. Replication cycle and safety considerations for retrovirus-mediated gene therapy. Ann N Y Acad Sci. 716:1994;59-70.
25. Hildinger M., Abel K.L., Ostertag W., Baum C. Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol. 73:1999;4083-4089.
26. Miller D.G., Adam M.A., Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 10:1990;4239-4242.
27. Challita P.M., Kohn D.B. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci U S A. 91:1994;2567-2571.
28. Smith K.T., Shepherd A.J., Boyd J.E., Lees G.M. Gene delivery systems for use in gene therapy an overview of quality assurance and safety issues . Gene Ther. 3:1996;190-200.
29. Neering S.J., Hardy S.F., Minamoto D., Spratt S.K., Jordan C.T. Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. Blood. 88:1996;1147-1155.
30. Wickham T.J., Mathias P., Cheresh D.A., Nemerow G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 73:1993;309-319.
31. Lehrman S. Virus treatment questioned after gene therapy death. Nature. 401:1999;517-518.
32. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 286:1999;2244-2245.
33. Wang Q., Finer M.H. Second-generation adenovirus vectors. Nat Med. 2:1996;714-716.
34. Snyder R.O., Spratt S.K., Lagarde C., Bohl D., Kaspar B., Sloan B., et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther. 8:1997;1891-1900.
35. Kessler P.D., Podsakoff G.M., Chen X., McQuiston S.A., Colosi P.C., Matelis L.A., et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A. 93:1996;14082-14087.
36. Monahan P.E., Samulski R.J. AAV vectors is clinical success on the horizon? Gene Ther. 7:2000;24-30.
37. Poeschla E., Corbeau P., Wong-Staal F. Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci U S A. 93:1996;11395-11399.
38. Ohm J.E., Shurin M.R., Esche C., Lotze M.T., Carbone D.P., Gabrilovich D.I. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol. 163:1999;3260-3268.
39. Gong J., Nikrui N., Chen D., Koido S., Wu Z., Tanaka Y., et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol. 165:2000;1705-1711.
40. Schnell T., Foley P., Wirth M., Munch J., Uberla K. Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther. 11:2000;439-447.
41. Todo T., Rabkin S.D., Sundaresan P., Wu A., Meehan K.R., Herscowitz H.B., et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther. 10:1999;2741-2755.
42. Frenkel N., Singer O., Kwong A.D. Minireview the herpes simplex virus amplicon - a versatile defective virus vector . Gene Ther. 1:(Suppl 1):1994;S40-S46.
43. Zhang G., Song Y.K., Liu D. Long-term expression of human alpha1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure. Gene Ther. 7:2000;1344-1349.
44. Anderson W.F., Killos L., Sanders-Haigh L., Kretschmer P.J., Diacumakos E.G. Replication and expression of thymidine kinase and human globin genes microinjected into mouse fibroblasts. Proc Natl Acad Sci U S A. 77:1980;5399-5403.
45. Yang N.S., Sun W.H. Gene gun and other non-viral approaches for cancer gene therapy. Nat Med. 1:1995;481-483.
46. Yang N.S., Burkholder J., Roberts B., Martinell B., McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci U S A. 87:1990;9568-9572.
47. Yang N.S., Sun W.H., McCabe D. Developing particle-mediated gene-transfer technology for research into gene therapy of cancer. Mol Med Today. 2:1996;476-481.
48. Woffendin C., Ranga U., Yang Z., Xu L., Nabel G.J. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci U S A. 93:1996;2889-2894.
49. Cheng L., Ziegelhoffer P.R., Yang N.S. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci U S A. 90:1993;4455-4459.
50. Toneguzzo F., Keating A. Stable expression of selectable genes introduced into human hematopoietic stem cells by electric field-mediated DNA transfer. Proc Natl Acad Sci U S A. 83:1986;3496-3499.
51. Van Tendeloo V.F., Willems R., Ponsaerts P., Lenjou M., Nijs G., Vanhove M., et al. High-level transgene expression in primary human T lymphocytes and adult bone marrow CD34+ cells via electroporation-mediated gene delivery. Gene Ther. 7:2000;1431-1437.
52. Potter H., Weir L., Leder P. Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Natl Acad Sci U S A. 81:1984;7161-7165.
53. Weaver J.C. Electroporation theory. Concepts and mechanisms. Methods Mol Biol. 55:1995;3-28.
54. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., et al. Lipofection a highly efficient, lipid-mediated DNA-transfection procedure . Proc Natl Acad Sci U S A. 84:1987;7413-7417.
55. Felgner P.L., Barenholz Y., Behr J.P., Cheng S.H., Cullis P., Huang L., et al. Nomenclature for synthetic gene delivery systems. Hum Gene Ther. 8:1997;511-512.
56. Branden L.J., Mohamed A.J., Smith C.I. A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat Biotechnol. 17:1999;784-787.
57. Cotten M., Langle-Rouault F., Kirlappos H., Wagner E., Mechtler K., Zenke M., et al. Transferrin-polycation-mediated introduction of DNA into human leukemic cells stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels . Proc Natl Acad Sci U S A. 87:1990;4033-4037.
58. Wagner E., Plank C., Zatloukal K., Cotten M., Birnstiel M.L. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes toward a synthetic virus-like gene-transfer vehicle . Proc Natl Acad Sci U S A. 89:1992;7934-7938.
59. Wagner E., Zatloukal K., Cotten M., Kirlappos H., Mechtler K., Curiel D.T., et al. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci U S A. 89:1992;6099-6103.
60. Calos M.P. The potential of extrachromosomal replicating vectors for gene therapy. Trends Genet. 12:1996;463-466.
61. Wohlgemuth J.G., Kang S.H., Bulboaca G.H., Nawotka K.A., Calos M.P. Long-term gene expression from autonomously replicating vectors in mammalian cells. Gene Ther. 3:1996;503-512.
62. Harrington J.J., Van Bokkelen G., Mays R.W., Gustashaw K., Willard H.F. Formation of de novo centromeres and construction of first-generation human artificial microchromosomes. Nat Genet. 15:1997;345-355.
63. Paterson B.M., Roberts B.E., Kuff E.L. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci U S A. 74:1977;4370-4374.
64. Stephenson M.L., Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A. 75:1978;285-288.
65. Simons R.W., Kleckner N. Translational control of IS10 transposition. Cell. 34:1983;683-691.
66. Chau Y.M., Pando S., Taylor H.S. HOXA11 silencing and endogenous HOXA11 antisense ribonucleic acid in the uterine endometrium. J Clin Endocrinol Metab. 87:2002;2674-2680.
67. Opalinska J.B., Gewirtz A.M. Nucleic-acid therapeutics basic principles and recent applications . Nat Rev Drug Discov. 1:2002;503-514.
68. Stasiak A. Getting down to the core of homologous recombination. Science. 272:1996;828-829.
69. Knauert M.P., Glazer P.M. Triplex forming oligonucleotides sequence-specific tools for gene targeting . Hum Mol Genet. 10:2001;2243-2251.
70. Gewirtz A.M., Sokol D.L., Ratajczak M.Z. Nucleic acid therapeutics state of the art and future prospects . Blood. 92:1998;712-736.
71. Stein C.A. How to design an antisense oligodeoxynucleotide experiment a consensus approach . Antisense Nucleic Acid Drug Dev. 8:1998;129-132.
72. Dominski Z., Kole R. Identification and characterization by antisense oligonucleotides of exon and intron sequences required for splicing. Mol Cell Biol. 14:1994;7445-7454.
73. Summerton J., Weller D. Morpholino antisense oligomers design, preparation, and properties . Antisense Nucleic Acid Drug Dev. 7:1997;187-195.
74. Crooke S.T. Molecular mechanisms of antisense drugs RNase H . Antisense Nucleic Acid Drug Dev. 8:1998;133-134.
75. Usman N., Blatt L.M. Nuclease-resistant synthetic ribozymes developing a new class of therapeutics . J Clin Invest. 106:2000;1197-1202.
76. Eckstein F. The hammerhead ribozyme. Biochem Soc Trans. 24:1996;601-604.
77. Nishikura K. A short primer on RNAi RNA-directed RNA polymerase acts as a key catalyst . Cell. 107:2001;415-418.
78. Elbashir S.M., Lendeckel W., Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15:2001;188-200.
79. Tuschl T. Expanding small RNA interference. Nat Biotechnol. 20:2002;446-448.
80. Ahlquist P. RNA-dependent RNA polymerases, viruses, and RNA silencing. Science. 296:2002;1270-1273.
81. Napoli C., Lemieux C., Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell. 2:1990;279-289.
82. Guo S., Kemphues K.J. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell. 81:1995;611-620.
83. Li Y.X., Farrell M.J., Liu R., Mohanty N., Kirby M.L. Double-stranded RNA injection produces null phenotypes in zebrafish. Dev Biol. 217:2000;394-405.
84. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498.
85. Yu J.Y., DeRuiter S.L., Turner D.L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A. 99:2002;6047-6052.
86. Bagot C.N., Kliman H.J., Taylor H.S. Maternal Hoxa10 is required for pinopod formation in the development of mouse uterine receptivity to embryo implantation. Dev Dyn. 222:2001;538-544.
87. Bagot C.N., Troy P.J., Taylor H.S. Alteration of maternal Hoxa10 expression by in vivo gene transfection affects implantation. Gene Ther. 7:2000;1378-1384.
88. Daftary GS, HS T. HOXA10 mediates differentiation of the endometrium in the absence of progesterone (Abstract). J Soc Gynecol Invest 2001;8:69A.
89. Charnock-Jones D.S., Sharkey A.M., Jaggers D.C., Yoo H.J., Heap R.B., Smith S.K. In-vivo gene transfer to the uterine endometrium. Hum Reprod. 12:1997;17-20.
90. Relloso M., Esponda P. In-vivo transfection of the female reproductive tract epithelium. Mol Hum Reprod. 6:2000;1099-1105.
91. Krumlauf R. Hox genes in vertebrate development. Cell. 78:1994;191-201.
92. McGinnis W., Krumlauf R. Homeobox genes and axial patterning. Cell. 68:1992;283-302.
93. Block K., Kardana A., Igarashi P., Taylor H.S. In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing mullerian system. FASEB J. 14:2000;1101-1108.
94. Taylor H.S., Vanden Heuvel G.B., Igarashi P. A conserved Hox axis in the mouse and human female reproductive system late establishment and persistent adult expression of the Hoxa cluster genes . Biol Reprod. 57:1997;1338-1345.
95. Satokata I., Benson G., Maas R. Sexually dimorphic sterility phenotypes in Hoxa10-deficient mice. Nature. 374:1995;460-463.
96. Taylor H.S., Arici A., Olive D., Igarashi P. HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium. J Clin Invest. 101:1998;1379-1384.
97. Benson G.V., Lim H., Paria B.C., Satokata I., Dey S.K., Maas R.L. Mechanisms of reduced fertility in Hoxa-10 mutant mice uterine homeosis and loss of maternal Hoxa-10 expression . Development. 122:1996;2687-2696.
98. Cermik D., Selam B., Taylor H.S. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 88:2003;238-243.
99. Daftary G.S., Taylor H.S. Hydrosalpinx fluid diminishes endometrial cell HOXA10 expression. Fertil Steril. 78:2002;577-580.
100. Taylor H.S., Bagot C., Kardana A., Olive D., Arici A. HOX gene expression is altered in the endometrium of women with endometriosis. Hum Reprod. 14:1999;1328-1331.
101. Zeyneloglu H.B., Arici A., Olive D.L. Adverse effects of hydrosalpinx on pregnancy rates after in vitro fertilization-embryo transfer. Fertil Steril. 70:1998;492-499.
102. Barnhart K., Dunsmoor-Su R., Coutifaris C. Effect of endometriosis on in vitro fertilization. Fertil Steril. 77:2002;1148-1155.
103. Homburg R., Armar N.A., Eshel A., Adams J., Jacobs H.S. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ. 297:1988;1024-1026.
104. Zhu L.J., Bagchi M.K., Bagchi I.C. Attenuation of calcitonin gene expression in pregnant rat uterus leads to a block in embryonic implantation. Endocrinology. 139:1998;330-339.
105. Ding Y.Q., Bagchi M.K., Bardin C.W., Bagchi I.C. Calcitonin gene expression in the rat uterus during pregnancy. Recent Prog Horm Res. 50:1995;373-378.
106. Ding Y.Q., Zhu L.J., Bagchi M.K., Bagchi I.C. Progesterone stimulates calcitonin gene expression in the uterus during implantation. Endocrinology. 135:1994;2265-2274.
107. Nishida M., Kasahara K., Kaneko M., Iwasaki H., Hayashi K. [Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors]. Nippon Sanka Fujinka Gakkai Zasshi. 37:1985;1103-1111.
108. Lessey B.A., Ilesanmi A.O., Castelbaum A.J., Yuan L., Somkuti S.G., Chwalisz K., et al. Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa) progesterone-induced expression of the alpha1 integrin . J Steroid Biochem Mol Biol. 59:1996;31-39.
109. Hortobagyi G.N., Ueno N.T., Xia W., Zhang S., Wolf J.K., Putnam J.B., et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects a phase I clinical trial . J Clin Oncol. 19:2001;3422-3433.